Resource impact statement
No significant resource impact is anticipated
NICE has recommended solriamfetol for treating excessive daytime sleepiness in adults with narcolepsy with or without cataplexy only if modafinil and either dexamfetamine or methylphenidate have not worked well enough or are not suitable.
This recommendation is not intended to affect treatment with solriamfetol that was started in the NHS before the guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 m people).
This is because the technology is a further treatment option and the overall cost of treatment will be similar.
Solriamfetol is commissioned by integrated care systems/clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: